Profit Alert: Innovio (INO)

OTC Journal Profit Alert: Inovio (INO)

Did you ever see the original 1981 Arthur movie starring Dudley Moore? It's hysterical- far better than last year's commercial bomb with Russel Brand. It's the story of wealthy, spoiled, New York socialite who parties hard and grows up.

There's a scene in the movie where Arthur goes into a flower shop. The proprietor- famous Broadway actor Lou Jaccoby, asks Arthur: "You're the rich one, aren't you. How Does It Feel To Have All That Money".

Arthur reflects for a moment, then responds "It Feels Great". Jacoby mutters to himself: "Stupid Question".

So, if you were to ask my how I feel about Inovio (INO) hitting and blowing through $2- I'll answer the same way Arthur did- "It Feels Great!!!!"

I love a good movie reference.

In fact, it feels great to be writing the OTC Journal these days. Followers are starting to do really well in LFAP, and I'm very pleased about that. NVLX has been a big win for those who have held from $.05. Recent Trading Alerts INO and BZIC are doing really well.

All in all, considering it's the teeth of the slow period in the summer, we're doing great.

And, speaking of doing great, have you watched INO of late?

Innovio (INO) was my trading alert back on May 21st. Click here to review that edition. INO is the biotech company working on a vaccine for the FLU and other under under served global diseases.

Here's an excerpt from the original presentation:

"if you want to consider this stock for a trade, set your target in the $.90 to $1.00 range. However, if you can think longer term at the front end of this secular bull market for small stocks in a biotech frenzy, a couple of very positive clinical results could send this one into the $3 to $5 range or higher in the next 19 months. That's a 470% gain from current levels."

I was looking to $3 to $5 in 19 months. We got to $2.20 in just over two months. That's 228% on your money from the original entry level of $.67.

As I've always said, with bio techs clinical results can really put a charge into share prices. INO was able to announce very positive results on their FLU vaccine in rats, and the stock just took off.

So, we haven't gotten to $3 to $5 yet, but we got to $2 in a big hurry, and 228% is pretty attractive.

You're probably thinking to yourself is he going to say "Buy, Sell, or Hold".

The answer- there is no answer for everyone.

I believe it's likely the stock will take a bit of a breather, so it might pullback. That would be a buying opportunity.

If you're not a seller at these levels, then you should be thinking Long Term, and not worry about a pullback.

If you're thinking a bit shorter term and find over 200% irresistible, now would be a good time to be a seller.

In short, the only thing I would not be is a buyer. Seller or holder is fine depending on you and what your objectives are and how much you like the company.

I believe a breather is in order, so if you want to be a buyer, have a little patience. My 19 month price target of $3 to $5 is probably low now, but a pullback into the $1.50 range would be no surprise.



The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at and/or the National Association of Securities Dealers ("NASD") at We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of


You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to